Cardiovascular disease in neurofibromatosis 1: Report of the NF1 Cardiovascular Task Force

Genetics in Medicine

Volumn 4, Issue 3, 2002, Pages 105-111

  Friedman, J M ^a   Arbiter, Jack ^b   Epstein, Jonathan A ^c   Gutmann, David H ^d   Huot, Stephen J ^e   Lin, Angela E ^f   McManus, Bruce ^a   Korf, Bruce R ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Congenital heart defects; Hypertension; Neurofibromatosis 1; Vasculopathy

Indexed keywords

CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONGENITAL HEART MALFORMATION; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MEDICAL RESEARCH; MEDICAL SOCIETY; NEUROFIBROMATOSIS; PATIENT CARE; PREVALENCE; REVIEW; VASCULAR DISEASE; ADVISORY COMMITTEE; GENETICS; PATHOPHYSIOLOGY;

ADVISORY COMMITTEES; CARDIOVASCULAR DISEASES; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION; NEUROFIBROMATOSIS 1;

EID: 0012376721     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/00125817-200205000-00002     Document Type: Review

References (55)

1. Friedman JM. Epidemiology of neurofibromatosistype 1. Am J Med Genet 1999;89: 1-6.
2. Friedman JM, Gutmann DU, MacCollin M, Riccardi VM. Neurofibromatosis: phenotype, natural history, and pathogenesis, 3rd ed. Baltimore: Johns Hopkins University Press, 1999.
3. Devaney K, Kapur SP, Patterson K, Chandra RS. Pediatric renal artery dysplasia: a morphologic study. Pediatr Pathol 1991;11:609-621.
4. Gutmann DH. Abnormalities of the nervous system. In: Friedman JM, Gutmann DH, MacCollin M, Riccardi VM, eds. Neurofibromatosis: phenotype, natural history, and pathogenesis. 3rd ed. Baltimore: Johns Hopkins University Press, 1999: 190-202.
5. Loh K-C, Shlossberg AH, Abbott EC, Salisbury SR, Tan M-H. Phaeochromoqtoma. A ten-year study. Q J Med 1997;90:51-60.
6. Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis: survival and malignant neoplasms. N Engl J Med 1986;314:1010-1015.
7. Zöller M, Rembeck B, Åkesson HO, Angervall L. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1: a twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta Derm Venerol 1995;75:136-140.
8. Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001;68:1110-1118.
9. Brasfield RD, DasGupta TK. Van Recklinghausen's disease. A clinicopathological study. Ann Surg 1972;175:86-104.
10. Salyer WR, Salyer DC. The vascular lesions of neurofibromatosis. Angiology 1974; 25:510-519.
11. Riccardi VM. Type 1 neurofibromatosis and the pediatric patient. Curr Probl Pediatr 1992;22:66-106; discussion 107.
12. Finley JL, Dabbs DJ. Renal vascular smooth muscle proliferation in neurofibromatosis. Hum Pathol 1988;19:107-110.
13. Schurch W, Messerli FH, Genest J, Lefebvre R, Roy P, Carter P, Rojo-Ortega JM. Arterial hypertension and neurofibromatosis: renal artery stenosis and coarctation of abdominal aorta. Can Med Assoc J 1975;113:879-885.
14. Lin AE, Birch PH, Korf BR, Tenconi R, Niimura M, Poyhonen M, Armfield Uhas K, Sigorini M, Virdis R, Romano C, Bonioli E, Wolkenstein P, Pivnick EK, Lawrence M, Friedman JM. Cardiovascular malformations and other cardiac abnormalities in neurofibromatosis 1 (NF1). Am J Med Genet 2000;95:108-117.
15. Zochodne D. Von Recklinghausen's vasculopathy. Am J Med Sci 1984:287:64-65.
16. Sobata E, Ohkuma H, Suzuki S. Cerebrovascular disorders associated with von Recklinghausen's neurofibromatosis: a case report. Neurosurgery 1988;22:544-549.
17. Brooks BS, Gammal TE, Adams RJ, Hartlage PL, Smith WB. MR imaging of moyamoya in neurofibromatosis. AJNR Am J Neuroradiol 1987;8:178-179.
18. Schievink WI, Michels W, Piepgras DG. Neurovascular manifestations of heritable connective tissue disorders. A review. Stroke 1994;25:889-903.
19. Reubi F. Les vaisseaux et les glandes endocrines dans la neurofibromatose: Le syndrome sympathicotonique dans le maladie de Recklinghausen. Schweiz Z Pathol Bacteriol 1944;7:168-236.
20. Feyrter F. ber die vasculäre Neurofibromatose, nach Utersuchungen am menschlichen Magen-Darmschlauch. Virchows Arch Pathol Anat 1949;317:221-265.
21. Orcel L, Chomette G. Anatomie pathologique vasculaire. Paris: Flammarion médecine-sciences, 1978.
22. Huffman JL, Gahtan V, Bowers VD, Mills JL. Neurofibromatosis and arterial aneurysms. Am Surg 1996;62:311-314.
23. Greene JF Jr, Fitzwater JE, Burgess J. Arterial lesions associated with neurofibromatosis. Am J Clin Pathol 1974;62:481-487.
24. Westenend PJ, Smedts F, de Jong MC, Lommers EJ, Assmann KJ. A 4-year-old boy with neurofibromatosis and severe renovascular hypertension due to renal arterial dysplasia. Am J Surg Pathol 1994;18:512-516.
25. Wasser MN, Westenberg J, van der Hulst VP, van Baalen J, van Bockel JH, van Erkel AR, Pattynama PM. Hemodynamic significance of renal artery stenosis: digital subtraction angiography versus systolically gated three-dimensional phase-contrast MR angiography. Radiology 1997;202:333-338.
26. Pickering TG, Sos TA, Vaughan ED Jr, Laragh JH. Differing patterns of renal vein renin secretion in patients with renovascular hypertension, and their role in predicting the response to angioplasty. Nephron 1986;44(suppl 1):8-11.
27. Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ("moyamoya" disease). Clin Neurol Neurosurg 1997;99:S238-S240.
28. Tedesco MA, Di Salvo G, Ratti G, Natale F, Calabrese E, Grassia C, Iacono A, Lama G. Arterial distensibility and ambulatory blood pressure monitoring in young patients with neurofibromatosis type 1. Am J Hypertens 2001;14:559-566.
29. Friedman JM. Vascular and endocrine abnormalities. In: Friedman JM, Gutmann DH, MacCollin M, Riccardi VM, eds. Neurofibromatosis: phenotype, natural history, and pathogenesis, 3rd ed. Baltimore: The Johns Hopkins University Press, 1999:274-296.
30. Sharma JB, Gulati N, Malik S. Maternal and perinatal complications in neurofibro-matosis during pregnancy. Int J Gynecol Obstet 1991;34:221-227.
31. Ferner RE. Medical complications of neurofibromatosis I. In: Huson SM, Hughes RAC, eds. The neurofibromatoses: a pathogenic and clinical overview. London: Chapman & Hall, 1994:316-33 0.
32. Mulvihill JJ. Malignancy. Epidemiologically associated cancers. In: Huson SM, Hughes RAC, eds. The neurofibromatoses: a pathogenic and clinical overview. London: Chapman & Hall, 1994:305-315.
33. Lie JT, Olney BA, Spittel JA. Perioperative hypertensive crisis and hemorrhagic diathesis: fatal complication of clinically unsuspected pheochromocytoma. Am Heart J 1980;100:716-722.
34. Young WF. Pheochromoqtoma and primary aldosteronism: diagnostic approaches. Endocrinol Metab Clin North Am 1997;26:801-827.
35. Eisenhofer G, Lenders AVM, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel- Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999;340:1872-1879.
36. Griffiths DFR, Williams GT, Williams ED. Duodenal carcinoid tumours, phaeochromocytoma and neurofibromatosis: islet cell tumour, phaeochromocytoma and the von Hippel-Lindau complex: two distinctive neuroendocrine syndromes. Q J Med 1987;64:769-782.
37. Anonymous. The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;57: 2413-2446.
38. Fossali E, Minoja M, Intermite R, Spreafico C, Casalini E, Serini F. Percutaneous transluminal renal angioplasty in neurofibromatosis. Pediatr Nephrol 1995;9:623-625.
39. Shapiro B, Fig LM. Management of pheochromocytoma. Endocrinol Metab Clin North Am 1989;18:443-481.
40. Hoffman JI. Congenital heart disease: incidence and inheritance. Pediatr Clin North Am 1990;37:25-43.
41. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF, Copeland NG. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994;8:1019-1029.
42. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994;7:353-361.
43. Viskochit DH. The structure and function of the NF1 gene: molecular pathophysiology. In: Friedman JM, Gutmann DH, MacCollin M, Riccardi VM, eds. Neurofibromatosis: phenotype, natural history, and pathogenesis, 3rd ed. Baltimore: The Johns Hopkins University Press, 1999:119-141.
44. Gutmann DH, Gurney JG. Other malignancies. In: Friedman JM, Gutmann DH, MacCollin M, Riccardi VM, eds. Neurofibromatosis: phenotype, natural history, and pathogenesis, 3rd ed. Baltimore: Johns Hopkins University Press, 1999;231-249.
45. Gutmann DH, Donahoe J, Brown T, James CD, Perry A. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol 2000;26:361-367.
46. Kluwe L, Hagel C, Tatagiba M, Thomas S, Stavrou D, Ostertag H, von Deimling A, Mautner VF. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol 2001;60:917-920.
47. Korf BR. Neurofibromas and malignant tumors of the peripheral nerve sheath. In: Friedman JM, Gutmann DH, MacCollin M, Riccardi VM, eds. Neurofibromatosis: phenotype, natural history, and pathogenesis, 3rd ed. Baltimore: The Johns Hopkins University Press, 1999:142-161.
48. Ingram DA, Van F, Travers JB, Wenning MJ, Hiatt K, New S, Hood A, Shannon K, Williams DA, Clapp DW. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumour suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp 2000;191:181-188.
49. Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M, Cashen A. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene 1999;18:4450-4459.
50. Bollag G, McCormick F, Clark R. Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. EMBO J 1993;12:1923-1927.
51. Gregory PE, Gutmann DH, Mitchell AL, Park S, Boguski M, Jacks T, Wood DL, Jove R, Collins FS. Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat Cell Mol Genet 1993;19:265-274.
52. Guo H, Tong J, Hannan F, Luo L, Zhong Y. A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature 2000;403:895-898.
53. Norton KK, Xu J, Gutmann DH. Expression of the neurofibromatosis 1 gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis 1995;2:13-21.
54. Ahlgren-Beckendorf JA, Maggio WW, Chen F, Kent TA. Neurofibromatosis I mRNA expression in blood vessels. Biochem Bhphys Res Commun 1993;197:1019-1024.
55. Hamilton SJ, Friedman JM. Insights into the pathogenesis of neurofibromatosis 1 vasculopathy. Clin Cenet 2000;58:341-344.